{
  "eval_id": "S01",
  "score": 100,
  "pass": true,
  "findings": [
    "Response accurately states Trodelvy's on-label indication for HR+/HER2- advanced breast cancer after prior endocrine therapy and at least two prior systemic therapies, including CDK4/6 inhibitor.",
    "References the TROPiCS-02 study as main evidence, which is appropriate.",
    "Directs to the EMA SmPC for further details and does not discuss off-label use.",
    "No promotional or non-compliant language detected."
  ],
  "rationale": "The response is strictly on-label, clinically relevant, and avoids any off-label or promotional content. It provides clear, accurate information and refers to the appropriate regulatory documents for further detail.",
  "timestamp": "2025-09-18T17:15:29.324881+00:00",
  "model": "gpt-4.1"
}